SHINE announces first sales of n.c.a. Lu-177
SHINE announces first sales of its non-carrier-added lutetium-177
SHINE announces first sales of its non-carrier-added lutetium-177
SHINE closes $80-million Series C financing supported by Fidelity Management and Research Company LLC
SHINE and IOCB Prague deliver patient dose quantities of lutetium-177 to GE Healthcare, advance therapeutic isotope toward commercialization
A crucial short-lived isotope is in short supply
One fear raised by those who oppose Britain’s leaving the European Union without a deal is that the import of radioactive isotopes for medicine would be at risk. These short-lived substances might, people wo
Recent Comments